S116836

立即咨询

S116836

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1257628-57-1

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议

产品介绍

S116836 是一种有效的，具有口服活性的 BCR-ABL 酪氨酸激酶抑制剂 (TKI)，可阻断野生型和 T315I BCR-ABL。S116836 能有效抑制 BCR-ABL 的磷酸化并诱导细胞凋亡 (apoptosis)。S116836 抑制 WT 和 T315I 突变型 BCR-ABL 肿瘤的生长，不会引起明显的心脏毒性。S116836 还抑制 SRC、LYN、HCK、LCK 和 BLK，以及受体酪氨酸激酶，如 FLT3、TIE2、KIT、PDGFR-β。具有抗肿瘤活性。

Cas No.	1257628-57-1
分子式	C₂₇H₂₁F₃N₆O
分子量	502.49
溶解度	DMSO : 65 mg/mL (129.36 mM; ultrasonic and warming and heat to 60°C)
储存条件	4°C, stored under nitrogen
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
产品描述	S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor (TKI), blocks both wild-type as well as T315I Bcr-Abl. S116836 potently inhibits the phosphorylation of BCR-ABL and induces apoptosis. S116836 inhibits growth of WT and T315I mutant BCR-ABL tumors and does not cause significant cardiotoxicity. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies[1][2][3]. S116836 (0.01-1 μM; 24 hours) significantly reduces the cellular proliferation of BaF3/WT and BaF3/T315I cells (IC50 values of 0.05 μM and 0.20 μM, respectively)[1].S116836 (0.01-1 μM； 24 hours) significantly downregulates the expression level of p-BCR-ABL in BaF3/WT cells[1].S116836 (0.01-1 μM; 24 hours) significantly downregulates the expression level of p-BCR-ABL in Imatinib-resistant BaF3/T315I cells[1].S116836 (0.01-1 μM; 24 hours) significantly downregulates the expression level of p-Crkl and p-STAT5 (downstream signaling proteins of BCR-ABL) in both BaF3/WT and BaF3/T315I cells[1].S116836 (0.1, 0.3, and 0.5 μM; 24 hours) arrests the BaF3/WT and BaF3/T315I cells in G0/G1 phase of the cell cycle[1].S116836 (0.3 and 0.5 μM; 24 hours) increases ROS production and decreases GSH levels in BaF3/WT and BaF3/T315I cells[1].S116836 (0.1, 0.3, and 0.5 μM; 24 hours) induces apoptosis in BaF3/WT and BaF3/T315I cells[1].SAHA and S116836 synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells[2].S116836 potently inhibits PDGFRα and its downstream signaling molecules such as STAT3, AKT, and Erk1/2. S116836 effectively inhibits the growth of the WT and T674I FIP1L1-PDGFRα-expressing neoplastic cells. S116836 induces intrinsic pathway of apoptosis as well as the death receptor pathway, coincided with up-regulation of the proapoptotic BH3-only protein Bim-EL through the Erk1/2 pathway[3]. S116836 (100 or 200 mg/kg; i.p.; q3d×6, athymic NCR nude mice) decreases the volume and weight of xenograft tumors expressing WT and T315I mutant BCR-ABL[1].S116836 (200mg/kg/d, oral gavage for 14 days) inhibits the growth of xenografted T674I-FIP1L1-PDGFRα cells in nude mice[3]. [1]. Gupta P, et al. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Cancer Lett. 2020;472:132-141. [2]. Bu Q, et al. SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol Ther. 2014;15(7):951-962. [3]. Shen Y, et al. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells. Oncotarget. 2014;5(21):10407-10420.